Reuters logo
BRIEF-Johnson & Johnson Q3 earnings per share $1.37
October 17, 2017 / 10:53 AM / 2 months ago

BRIEF-Johnson & Johnson Q3 earnings per share $1.37

Oct 17 (Reuters) - Johnson & Johnson:

* Johnson & Johnson reports 2017 third-quarter results

* Q3 earnings per share $1.37

* Q3 sales $19.7 billion versus I/B/E/S view $19.28 billion

* Q3 earnings per share view $1.80 -- Thomson Reuters I/B/E/S

* Sees FY 2017 adjusted earnings per share $7.25 to $7.30

* Q3 adjusted non-GAAP earnings per share $1.90 excluding items

* Sees FY 2017 sales $76.1 billion to $76.5 billion

* Qtrly ‍worldwide pharmaceutical sales of $9.7 billion for Q3 2017 represented an increase of 15.4% versus prior year​

* Excluding net impact of acquisitions and divestitures, on operational basis, worldwide, domestic, international sales each increased 3.8% in quarter​

* Worldwide medical devices sales of $6.6 billion for Q3 2017 represented an increase of 7.1% versus prior year​

* Qtrly ‍worldwide consumer sales of $3.4 billion for Q3 2017 represented an increase of 2.9% versus prior year​

* Qtrly worldwide Velcade sales $273‍​ million versus $290 million in Q2 2017

* Qtrly worldwide Remicade sales $‍​1,647 million versus $1,530 million in Q2 2017

* Qtrly worldwide Zytiga sales $669‍​ million versus $558 million in Q2 2017

* Qtrly worldwide Invokana/Invokamet sales $265‍​ million versus $295 million in Q2

* Third-quarter 2017 net earnings included after-tax intangible amortization expense of approximately $0.9 billion​

* Third-quarter 2017 net earnings included charge for after-tax special items of approximately $0.5 billion​

* ‍“Company has made a decision not to pursue global approvals of sirukumab for treatment of moderately to severely active rheumatoid arthritis”​

* Clinical trial for talacotuzumab, an investigational compound being studied in patients with acute myeloid leukemia, has been discontinued​

* FY2017 earnings per share view $7.18, revenue view $75.83 billion -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below